Trastuzumab Rezetecan

DRUG18 trials

Sponsors

Henan Cancer Hospital, Fudan University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen University, Sheng Zhang

Conditions

Advanced Breast CancerAdvanced Malignant Solid NeoplasmAdvanced Solid Tumor CancerAdvanced Urothelial CarcinomaAntibody-drug ConjugatesBiliary Tract NeoplasmsBiliary Tract Neoplasms ImmunotherapyBrain Metastases

Phase 2

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Not yet recruitingNCT07047755

Henan Cancer HospitalBreast Cancer

Start: 2025-07-01End: 2031-02-28Target: 48Updated: 2025-07-02

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

RecruitingNCT07100600

Henan Cancer HospitalBrain Metastases, HER2-positive Advanced Breast Cancer, Radiotherapy

Start: 2025-08-30End: 2032-12-30Target: 224Updated: 2025-08-11

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Not yet recruitingNCT07179939

Fudan UniversityHER2-positive Breast Cancer

Start: 2025-09-10End: 2031-12-30Target: 288Updated: 2025-09-18

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

RecruitingNCT07203729

Cancer Institute and Hospital, Chinese Academy of Medical SciencesHER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

Start: 2026-03-01End: 2030-12-30Target: 184Updated: 2026-03-16

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

RecruitingNCT07241793

Sun Yat-sen UniversityAdvanced Urothelial Carcinoma, Urothelial Carcinoma, Urothelial Carcinoma Recurrent

Start: 2025-11-20End: 2031-07-01Target: 96Updated: 2026-04-30

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

RecruitingNCT07309770

Sheng ZhangAdvanced Solid Tumor Cancer, Antibody-drug Conjugates, Urachal Cancer

Start: 2025-12-18End: 2028-03-11Target: 90Updated: 2025-12-30

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

Not yet recruitingNCT07416253

Henan Cancer HospitalBreast Cancer

Start: 2026-03-01End: 2030-07-01Target: 68Updated: 2026-02-18

Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities

Not yet recruitingNCT07630077

Sun Yat-sen UniversityNon Small Cell Lung Cancer

Start: 2026-07-01End: 2028-07-01Target: 30Updated: 2026-06-05

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

Not yet recruitingNCT07631884

Haihua YuanAdvanced Malignant Solid Neoplasm, Biliary Tract Neoplasms, Cervical Neoplasms +13

Start: 2026-06-15End: 2028-12-31Target: 15Updated: 2026-06-08

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

RecruitingNCT07670273

Peking Union Medical College HospitalBiliary Tract Neoplasms Immunotherapy

Start: 2026-04-29End: 2028-04-29Target: 70Updated: 2026-06-26

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

Not yet recruitingNCT07699952

Yongsheng WangEGFR Activating Mutation, HER2, Lung Cancer (NSCLC)

Start: 2026-09-09End: 2029-03-01Target: 35Updated: 2026-08-17

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

RecruitingNCT07704177

Peking Union Medical College HospitalBiliary Tract Neoplasms Immunotherapy

Start: 2026-04-15End: 2028-04-15Target: 70Updated: 2026-07-15

Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC

RecruitingNCT07741448

Start: 2026-08-15End: 2029-08-15Target: 54Updated: 2026-08-03

Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer

Not yet recruitingNCT07766772

Fujian Cancer HospitalAdvanced Breast Cancer, HER2 + Breast Cancer

Start: 2026-09-30End: 2031-12-31Target: 50Updated: 2026-08-14

A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC

Not yet recruitingNCT07778745

Tianjin Medical University Cancer Institute and HospitalNSCLC

Start: 2026-08-20End: 2029-08-30Target: 37Updated: 2026-08-21

Phase 4

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Not yet recruitingNCT07589699

The First Affiliated Hospital with Nanjing Medical UniversityBreast Cancer, Early-stage Breast Cancer, HER2-positive Breast Cancer +1

Start: 2026-05-31End: 2031-12-31Target: 59Updated: 2026-05-15

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

RecruitingNCT07600164

Peking University People's HospitalAdvanced Breast Cancer, HER2 + Breast Cancer

Start: 2026-07-06End: 2031-12-30Target: 500Updated: 2026-07-13

Unknown Phase

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Active, not recruitingNCT07387874

LixiaolingRecurrent or Metastatic Solid Tumors

Start: 2025-07-10End: 2028-07-01Target: 30Updated: 2026-02-04